Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection

AIDS Research and Human Retroviruses

Volumn 26, Issue 4, 2010, Pages 379-387

  Steingrover, Radjin ^a,b,c   Garcia, Evian Fernandez ^c   Van Valkengoed, Irene G M ^a   Bekker, Vincent ^a   Bezemer, Daniela ^d   Kroon, Frank P ^e   Dekker, Linda ^f   Prins, Maria ^a,g   De Wolf, Frank ^d   Lange, Joep M A ^a,b,c   Prins, Jan M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b National Antiretroviral Therapy Evaluation Center   (Netherlands)

^c Intl Antiviral Ther Eval Center   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CENTRAL LABORATORY   (Netherlands)

^g DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECT; EARLY INTERVENTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREDICTION; PRIMARY INFECTION; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; NETHERLANDS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951798589     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0041     Document Type: Article

References (24)

1. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al.: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+and CD4+T lymphocytes. Proc Natl Acad Sci USA 2000;97(7):3382-3387.
2. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407(6803):523-526.
3. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, et al.: HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+T cells endowed with proliferative capacity. J Exp Med 2003;198(12):1909-1922.
4. Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, et al.: Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS 2005;19(11):1145-1154.
5. Kinloch-de Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333(7):408-413.
6. Niu MT, Bethel J, Holodniy M, Standiford HC, and Schnittman SM: Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: A randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 1998;178(1):80-91.
7. Girard PM, Schneider V, Dehee A, Mariot P, Jacomet C, Delphin N, et al.: Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS 2001;15(2):275-277.
8. Markowitz M, Jin X, Hurley A, Simon V, Ramratnam B, Louie M, et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186(5):634-643. (Pubitemid 34925535)
9. Fidler S, Oxenius A, Brady M, Clarke J, Cropley I, Babiker A, et al.: Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16(15):2049-2054.
10. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al.: Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18(18):2361-2369.
11. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al.: Limited durability of viral control following treated acute HIV infection. PLoS Med 2004;1(2):e36.
12. Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, et al.: A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194(6): 725-733.
13. Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, and Phillips AN: Effect of transient antiretroviral treatment during acute HIV infection: Comparison of the Quest trial results with CASCADE natural history study. Antivir Ther 2007;12(2):189-193.
14. Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, et al.: Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis 2006;194(6):734-739.
15. Keet IP, Krijnen P, Koot M, Lange JM, Miedema F, Goudsmit J, et al.: Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993;7(1):51-57.
16. Sinicco A, Fora R, Sciandra M, Lucchini A, Caramello P, and Gioannini P: Risk of developing AIDS after primary acute HIV-1 infection. J Acquir Immune Defic Syndr 1993;6(6): 575-581. (Pubitemid 23186097)
17. Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, et al.: Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9(3): 305-310.
18. Veugelers PJ, Kaldor JM, Strathdee SA, Page-Shafer KA, Schechter MT, Coutinho RA, et al.: Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. J Infect Dis 1997;176(1):112-117.
19. van Griensven GJ, Tielman RA, Goudsmit J, van der NJ, de Wolf F, de Vroome EM, et al.: Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987;125(6):1048-1057. (Pubitemid 17099050)
20. van den Hoek JA, Coutinho RA, van Haastrecht HJ, van Zadelhoff AW, and Goudsmit J: Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988;2(1):55-60.
21. van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al.: Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003;17(15):2227-2236. (Pubitemid 37338896)
22. Jansen CA, De Cuyper IM, Hooibrink B, van der Bij AK, van Baarle D, and Miedema F: Prognostic value of HIV-1 Gagspecific CD4+T-cell responses for progression to AIDS analyzed in a prospective cohort study. Blood 2006;107(4): 1427-1433.
23. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al.: Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126(12):946-954.
24. Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, et al.: Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006;42(7):1024-1031.